Home Featured Page 110

Featured

Latest

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

Blossom – Making Psychedelic Education Accessible with David Drapkin from Psychedelics...

Fierce Healthcare – Psychedelics Today to offer yearlong certificate course on...

Taos News – Psychedelic therapy gains support in NM, momentum nationwide

AP News – Psychedelics Today Re-Launches Vital Diversity, Equity and Inclusion...

AP News – Psychedelics Today Launches “Psychedelics Tonight”

The Pharma Letter – The psychedelic medicine renaissance: how could the...

Enosis Therapeutics announces its response to Australian TGA decision, Plans to...

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results ...

1...109110111...306 Page 110 of 306

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

Blossom – Making Psychedelic Education Accessible with David Drapkin from Psychedelics...

PT394 – We Are The Medicine

Fierce Healthcare – Psychedelics Today to offer yearlong certificate course on...

Taos News – Psychedelic therapy gains support in NM, momentum nationwide

AP News – Psychedelics Today Re-Launches Vital Diversity, Equity and Inclusion...

AP News – Psychedelics Today Launches “Psychedelics Tonight”

The Pharma Letter – The psychedelic medicine renaissance: how could the...

Enosis Therapeutics announces its response to Australian TGA decision, Plans to...

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results ...

EDITOR PICKS

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY